• LAST PRICE
    19.4300
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-0.2567%)
  • Bid / Lots
    19.3700/ 10
  • Ask / Lots
    19.9700/ 10
  • Open / Previous Close
    19.4800 / 19.4800
  • Day Range
    Low 19.3600
    High 19.9200
  • 52 Week Range
    Low 15.3100
    High 26.8400
  • Volume
    448,695
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 19.48
TimeVolumeXNCR
09:32 ET275019.48
09:34 ET10019.36
09:38 ET90019.54
09:41 ET10019.545
09:45 ET10019.54
09:52 ET10019.54
09:54 ET132619.57
09:56 ET20019.59
09:59 ET70019.53
10:01 ET49419.61
10:03 ET110719.63
10:06 ET90019.59
10:08 ET199019.68
10:10 ET80019.585
10:12 ET27719.68
10:14 ET30019.565
10:17 ET10019.57
10:19 ET38419.56
10:24 ET10019.535
10:26 ET10019.49
10:33 ET12519.5
10:35 ET10019.49
10:42 ET140019.63
10:46 ET120019.67
10:48 ET585919.76
10:50 ET137319.85
10:51 ET20919.78
11:06 ET40019.915
11:09 ET10019.91
11:13 ET100019.87
11:18 ET13819.83
11:22 ET50019.745
11:24 ET10019.735
11:26 ET90019.63
11:27 ET90019.61
11:29 ET190419.72
11:31 ET21919.67
11:33 ET70019.65
11:36 ET20019.7
11:38 ET10019.72
11:45 ET20019.66
11:47 ET20019.6675
11:58 ET10019.645
12:00 ET10019.645
12:02 ET76719.6079
12:03 ET89619.64
12:05 ET99719.6
12:09 ET21719.58
12:12 ET10019.59
12:14 ET20019.6
12:18 ET40019.6
12:20 ET28419.61
12:21 ET20019.6
12:23 ET220019.6
12:27 ET203619.635
12:30 ET10019.655
12:32 ET10019.645
12:34 ET109019.62
12:38 ET34419.64
12:39 ET10019.64
12:45 ET10019.66
12:50 ET170019.62
12:52 ET20819.593
12:54 ET20019.59
12:56 ET2653719.53
12:57 ET80019.64
01:03 ET14719.61
01:06 ET19419.61
01:12 ET359019.64
01:14 ET10019.64
01:19 ET10019.64
01:21 ET10019.64
01:26 ET10019.645
01:32 ET10019.645
01:37 ET10019.645
01:39 ET60019.68
01:44 ET3937219.615
01:46 ET10019.65
01:50 ET150019.685
01:51 ET30019.685
01:53 ET20019.69
01:55 ET12219.695
01:57 ET10019.695
02:06 ET10019.705
02:08 ET969019.66
02:11 ET102619.66
02:13 ET10019.64
02:15 ET30019.635
02:18 ET45819.645
02:22 ET10019.65
02:24 ET10019.63
02:29 ET93419.58
02:31 ET40019.62
02:36 ET70019.6
02:40 ET10019.59
02:44 ET13319.59
02:47 ET20019.58
02:49 ET11219.563
02:54 ET12519.54
02:58 ET200619.55
03:00 ET72719.55
03:02 ET53719.51
03:03 ET71219.52
03:05 ET69919.61
03:09 ET35019.57
03:14 ET20019.57
03:16 ET40019.6
03:18 ET20019.62
03:20 ET104419.575
03:25 ET89519.55
03:27 ET10019.535
03:30 ET10019.535
03:32 ET122219.46
03:34 ET10019.44
03:36 ET10019.46
03:38 ET10019.48
03:39 ET90619.465
03:41 ET130519.41
03:43 ET49819.43
03:45 ET212719.453
03:48 ET50019.432
03:50 ET31419.45
03:52 ET119419.42
03:54 ET371819.41
03:56 ET918119.54
03:57 ET120019.43
03:59 ET20243219.43
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXNCR
Xencor Inc
1.4B
-6.7x
---
United StatesTVTX
Travere Therapeutics Inc
1.2B
-3.0x
---
United StatesARDX
Ardelyx Inc
1.4B
-21.4x
---
United StatesAUPH
Aurinia Pharmaceuticals Inc
978.1M
-19.4x
---
United StatesDVAX
Dynavax Technologies Corp
1.4B
105.1x
---
United StatesGYRE
Gyre Therapeutics Inc
1.2B
-15.0x
---
As of 2024-10-08

Company Information

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Contact Information

Headquarters
465 N. HALSTEAD ST., SUITE 200PASADENA, CA, United States 91107
Phone
626-305-5900
Fax
626-305-0350

Executives

President, Chief Executive Officer, Founder and Director
Bassil Dahiyat
Senior Vice President, Chief Financial Officer
Bart Cornelissen
Executive Vice President - Research, Chief Scientific Officer
John Desjarlais
Executive Vice President, Chief Development Officer
Nancy Valente
Senior Vice President, General Counsel, Corporate Secretary
Celia Eckert

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.4B
Revenue (TTM)
$133.6M
Shares Outstanding
69.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.67
EPS
$-2.90
Book Value
$10.96
P/E Ratio
-6.7x
Price/Sales (TTM)
10.2
Price/Cash Flow (TTM)
---
Operating Margin
-145.10%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.